Undisclosed Bladder Program
Underserved bladder disorders (e.g., overactive bladder, interstitial cystitis)
Pre-clinicalActive
Key Facts
Indication
Underserved bladder disorders (e.g., overactive bladder, interstitial cystitis)
Phase
Pre-clinical
Status
Active
Company
About EG 427
EG 427 is a Paris-based gene therapy startup pioneering the use of engineered, non-replicative Herpes Simplex Virus 1 (HSV-1) vectors as a DNA medicine platform. The company aims to tackle localized chronic diseases by enabling precise, long-term, and safe transgene expression, initially targeting disorders of the peripheral nervous system. It has secured non-dilutive funding from French government entities and is building its pipeline and manufacturing capabilities. EG 427 is currently in a pre-clinical development stage, actively recruiting to advance its lead program for bladder disorders.
View full company profile